Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr Sells 1,140 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr sold 1,140 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now owns 7,012 shares of the company’s stock, valued at $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Patricia Carr also recently made the following trade(s):

• On Thursday, February 27th, Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $136.05 on Friday. The company’s 50 day simple moving average is $129.17 and its 200-day simple moving average is $120.60. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The company has a market capitalization of $8.26 billion, a price-to-earnings ratio of 19.16, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Analyst Ratings Changes

Several research analysts have recently weighed in on JAZZ shares. Morgan Stanley restated an “overweight” rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. HC Wainwright boosted their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research note on Monday. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Barclays reiterated an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Finally, UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $190.53.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $25,000. Quadrant Capital Group LLC lifted its stake in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP boosted its holdings in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 183 shares during the period. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $28,000. Finally, Allianz SE purchased a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.